In recent years, interest has grown around two investigational peptides, BPC-157 and TB-500, proposed as part of a combined research-oriented protocol to explore tissue regeneration, angiogenesis, and ...

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of ...

Phase II trial of dose-escalated sorafenib in advanced solid tumors. A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell ...

Researchers at Johns Hopkins University have identified a process in the eye that may explain why biologic drugs for treating age-related macular degeneration (AMD) fail in some patients. Using that ...

Researchers led by a team at the Wilmer Eye Institute, Johns Hopkins Medicine, have discovered why vision in some patients with neovascular (nv) or “wet” age-related macular degeneration (nvAMD, or ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...